Please complete the CAPTCHA to continue
@celonic.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Andreas Herrmann is listed as Biotech CEO @ Baliopharm AG | Innovative Drug Development at Corat Therapeutics, based in Basel, Basel, Switzerland. AeroLeads shows a work email signal at celonic.com and a matched LinkedIn profile for Andreas Herrmann.
Andreas Herrmann previously worked as Chief Executive Officer at Corat Therapeutics and CEO at Valerius Biopharma Ag. Andreas Herrmann holds Phd, Biochemistry from University Of Cologne.
This section adds company-level context without repeating Andreas Herrmann's masked contact details.
AeroLeads found 1 current-domain work email signal for Andreas Herrmann. Compare company email patterns before reaching out.
CEO at Baliopharm AG | Innovative antibodies & formatsCEO at Corat Therapeutics | Covid-19 Drug DeveloperBiotech Entrepreneur with Multiple Antibody TherapeuticsAs the CEO of Corat Therapeutics and Baliopharm AG, I lead the development of innovative biopharmaceuticals for the treatment of Covid-19 and other unmet medical needs. With over 20 years of experience in the biotechnology industry, I have founded and built several successful companies, ranging from service to product development, and secured multiple patents, publications, and partnerships.My core competencies include antibodies, pharmaceutics, biosimilars, biotechnology, and business development. I have a strong track record of delivering results, such as advancing our lead compound COR-101, a fully human antibody derived from Covid-19 patients, into clinical trials, and creating a pipeline of innovative antibodies, including ATROSIMAB for CNS, cardiovascular and respiratory disease. My mission is to provide affordable and accessible treatment options for patients with life-threatening diseases, and to contribute to the global fight against the pandemic.
Listed skills include Biopharmaceuticals, Gmp, Biotechnology, R&D, and 32 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Corat Therapeutics is a biotech company founded in June 2020 dedicated to the development of biopharmaceutical drugs to treat Covid-19. Our lead compound COR-101 is an innovative fully human, antibody derived from a antibody library made from reconvalescent Covid-19 patients which is neutralising SARS-CoV-2. COR-101 reveals picomolar affinity, 100%.
Basel, CH-, CH
Valerius Biopharma AG is a biopharmaceutical company that has been founded to provide interchangeable treatment options for high-priced biologics, by developing specialty biosimilars including but not limited to orphan drug biosimilars. Our interdisciplinary team of experts combines decades of experience gained in the biotechnology and biosimilar industry..
Baliopharm develops innovative biopharmaceuticals for the treatment of autoimmune diseases and tumor indications. The product pipeline consists about two products: a humanized anti-TNF-receptor 1 specific antibody, which has been used in clinical phase I study in healthy volunteers, and is dedicated to be used for various autoimmune diseases such as RA.
Probiocon GmbH is a consulting company for pharmaceutical companies offering support in corporate and business development, interims management, as well as in process, preclinical and early clinical development of innovative biopharmaceuticals and biosimilars. In addition we help clients in finding the right oursourcing partner for CMC development of.
Reykjavik, -, IS
Alvotech is going to become one of the leading companies for the development of biosimilar compounds derived from mammalian cell culture technology. Alvotech has build a 14.000 sqm GMP facility for R&D and commercial supply of biosimilar monoclonal antibodies in Reykjavik. This plant using newest disposable Technologies with 16.000 L scale production.
Basel, CH
Building up the Company from scratch with two Locations in Germany and Switzerland up to 85 employees. Build up facilities for GMP production up to 1000 L scale and GLP analytical work for preclinical and clinincal studies. Celonic is a full contract manufacturing organization providing Services from cell-line development up to Phase II production of API.
Responsible for the Process Development, GMP Production and GLP Analytic of companies biopharmaceutical products
Heading the R&D programm of Cardiogene AG with respect to gene therapeutics and immunotherpeutics
heading group of cardiovascular gene therapy
Quick answers generated from the profile data available on this page.
Andreas Herrmann works for Corat Therapeutics.
Andreas Herrmann is listed as Biotech CEO @ Baliopharm AG | Innovative Drug Development at Corat Therapeutics.
AeroLeads has found 1 work email signal at @celonic.com for Andreas Herrmann at Corat Therapeutics.
Andreas Herrmann is based in Basel, Basel, Switzerland while working with Corat Therapeutics.
Andreas Herrmann has worked for Corat Therapeutics, Valerius Biopharma Ag, Baliopharm Ag, Probiocon Gmbh, and Alvotech Ehf / Alvotech Swiss.
You can use AeroLeads to view verified contact signals for Andreas Herrmann at Corat Therapeutics, including work email, phone, and LinkedIn data when available.
Andreas Herrmann holds Phd, Biochemistry from University Of Cologne.
Andreas Herrmann is listed with skills including Biopharmaceuticals, Gmp, Biotechnology, R&D, Glp, Contract Manufacturing, Pharmaceutical Industry, and Technology Transfer.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts